Broad-spectrum coronavirus antiviral drug discovery

Expert Opinion on Drug Discovery

Volumn 14, Issue 4, 2019, Pages 397-412

  Totura, Allison L ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

acute respiratory distress syndrome; Antiviral; ARDS; bat; broad spectrum; camel; civet; coronavirus; emerging virus; highly pathogenic virus; human cases; in vitro model; interferon; lopinavir; MERS; MERS CoV; Middle East respiratory syndrome; pneumonia; primate model; respiratory; ribavirin; rodent model; SARS; SARS CoV; severe acute respiratory syndrome; therapeutic; zoonosis; zoonotic

Indexed keywords

ANTIVIRUS AGENT; LOPINAVIR PLUS RITONAVIR; MONOCLONAL ANTIBODY; NEUTRALIZE STRUCTURAL PROTEIN; REMDESIVIR; RIBAVIRIN; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS VACCINE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIVIRAL ACTIVITY; CORONAVIRIDAE INFECTION; CORONAVIRINAE; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVERSE GENETICS; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; ANIMAL; CORONAVIRUS INFECTION; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECT; ISOLATION AND PURIFICATION; PROCEDURES; SARS CORONAVIRUS; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 85062938970     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2019.1581171     Document Type: Review

References (127)

1. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953–1966.
2. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976.
3. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820.
4. Lew TWK, Kwek T-K, Tai D, et al. Acute respiratory distress syndrome in critically Ill patients with severe acute respiratory syndrome. JAMA. 2003;290(3):374–380. Available from: http://jama.ama-assn.org/cgi/content/abstract/290/3/374
5. WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. [cited 2019 Jan25]. Available from: http://www.who.int/csr/sars/country/table2004_04_21/en/index.html
6. WHO. MERS situation update. Dec 2018 [cited 2019 Jan25]. Available from: http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-december-2018.html
7. Corman VM, Muth D, Niemeyer D, et al. Chapter eight - hosts and sources of endemic human coronaviruses. In: Kielian M, Mettenleiter TC, Roossinck MJ, editors. Advances in virus research. Vol. 100. Cambridge, MA: Academic Press; 2018. p. 163–188.
8. Davis BM, Foxman B, Monto AS, et al. Human coronaviruses and other respiratory infections in young adults on a university campus: prevalence, symptoms, and shedding. Influenza Other Respir Viruses. 2018;12(5):582–590.
9. Drexler JF, Corman VM, Drosten C., Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. Antiviral Res. 2014;101:45–56. Available from: http://www.sciencedirect.com/science/article/pii/S0166354213003161
10. Ge X-Y, Li J-L, Yang X-L, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. [Letter]. Nature. 2013;503(7477):535–538.
11. Ziad AM, Nischay M, Kevin JO, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis J. 2013;19(11):1819. Available from: http://wwwnc.cdc.gov/eid/article/19/11/13-1172
12. Woo PCY, Wang M, Lau SKP, et al. Comparative analysis of twelve genomes of three novel Group 2c and Group 2d coronaviruses reveals unique group and subgroup features. J Virol. 2007;81(4):1574–1585. Available from: http://jvi.asm.org/content/81/4/1574.abstract
13. Lau SKP, Woo PCY, Li KSM, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA. 2005;102(39):14040–14045. Available from: http://www.pnas.org/content/102/39/14040.abstract
14. Anthony SJ, Gilardi K, Menachery VD, et al. Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus. mBio. 2017;8(2). DOI:10.1128/mBio.00373-17
15. Menachery VD, Yount BL, Jr, Debbink K, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015;21:1508–1513.
16. Menachery VD, Yount BL, Sims AC, et al. SARS-like WIV1-CoV poised for human emergence. Proc Nat Acad Sci. 2016;113(11):3048–3053. Available from: http://www.pnas.org/content/113/11/3048.abstract
17. Woo PCY, Lau SKP, Li KSM, et al. Molecular diversity of coronaviruses in bats. Virology. 2006;351(1):180–187. Available from: http://www.sciencedirect.com/science/article/pii/S0042682206001425
18. Yang Y, Du L, Liu C, et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Nat Acad Sci. 2014;111(34):12516–12521. Available from: http://www.pnas.org/content/111/34/12516.abstract
19. Wang Q, Qi J, Yuan Y, et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe. 2014;16(3):328–337. Available from: http://www.sciencedirect.com/science/article/pii/S1931312814003011
20. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science. 2003;302(5643):276–278. Available from: http://www.sciencemag.org/content/302/5643/276.abstract
21. Alagaili AN, Briese T, Mishra N, et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio. 2014;5(2). DOI:10.1128/mBio.00884-14
22. Song H-D, Tu -C-C, Zhang G-W, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci USA. 2005;102(7):2430–2435. Available from: http://www.pnas.org/content/102/7/2430.abstract
23. Sheahan T, Rockx B, Donaldson E, et al. Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus. J Virol. 2008;82(17):8721–8732. Available from: http://jvi.asm.org/content/82/17/8721.abstract
24. Thompson MG, Shay DK, Zhou H, et al. Estimates of deaths associated with seasonal influenza - United States, 1976–2007. MMWR Morb Mortal Wkly Rep. 2010;59(33):1057–1062.
25. Korea Centers for Disease, C., & Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect. 2015;6(4):269–278. Available from: http://www.sciencedirect.com/science/article/pii/S221090991530045X
26. Mackay IM, Arden KE., MERS coronavirus: diagnostics, epidemiology and transmission. Virol J. 2015;12:222. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687373/
27. Müller MA, Meyer B, Corman VM, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis. 2015;15(5):559–564. Available from: http://www.sciencedirect.com/science/article/pii/S1473309915700903
28. Chan J, Ng C, Chan Y, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58(8):686–689. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746764/
29. Cockrell AS, Beall A, Yount B, et al. Efficient reverse genetic systems for rapid genetic manipulation of emergent and preemergent infectious coronaviruses. In: Perez DR, editor. Reverse genetics of RNA viruses: methods and Protocols. New York: Springer New York; 2017. p. 59–81.
30. Yount B, Curtis KM, Baric RS. Strategy for systematic assembly of large RNA and DNA genomes: transmissible gastroenteritis virus model. J Virol. 2000;74(22):10600–10611. Available from: http://jvi.asm.org/content/74/22/10600.abstract
31. Yount B, Denison MR, Weiss SR, et al. Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol. 2002;76(21):11065–11078. Available from: http://jvi.asm.org/content/76/21/11065.abstract
32. Yount B, Curtis KM, Fritz EA, et al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Nat Acad Sci. 2003;100(22):12995–13000. Available from: http://www.pnas.org/content/100/22/12995.abstract
33. Scobey T, Yount BL, Sims AC, et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Nat Acad Sci. 2013;110(40):16157–16162. Available from: http://www.pnas.org/content/110/40/16157.abstract
34. Rockx B, Sheahan T, Donaldson E, et al. Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. J Virol. 2007;81(14):7410–7423. Available from: http://jvi.asm.org/content/81/14/7410.abstract
35. Sheahan T, Rockx B, Donaldson E, et al. Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium. J Virol. 2008;82(5):2274–2285. Available from: http://jvi.asm.org/content/82/5/2274.abstract
36. Rockx B, Feldmann F, Brining D, et al. Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques. PLoS ONE. 2011;6(4):e18558.
37. Becker MM, Graham RL, Donaldson EF, et al. Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc Nat Acad Sci. 2008;105(50):19944–19949. Available from: http://www.pnas.org/content/105/50/19944.abstract
38. Agnihothram S, Yount BL, Donaldson EF, et al. A mouse model for betacoronavirus Subgroup 2c Using a Bat coronavirus strain HKU5 variant. mBio. 2014;5(2). DOI:10.1128/mBio.00047-14
39. Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120–134. Available from: http://www.sciencedirect.com/science/article/pii/S0168170214004961
40. Chan JF-W, Chan K-H, Choi GK-Y, et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis. 2013;207(11):1743–1752. Available from: http://jid.oxfordjournals.org/content/207/11/1743.abstract
41. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med. 2004;10(4):368–373. Available from: http://www.nature.com/nm/journal/v10/n4/suppinfo/nm1024_S1.html
42. Pyrc K, Sims AC, Dijkman R, et al. Culturing the unculturable: human coronavirus HKU1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures. J Virol. 2010;84(21):11255–11263. Available from: http://jvi.asm.org/content/84/21/11255.abstract
43. Lambert F, Jacomy H, Marceau G, et al. Titration of human coronaviruses, HCoV-229E and HCoV-OC43, by an indirect immunoperoxidase assay. In: Cavanagh D, editor. SARS- and other coronaviruses. Vol. 454. Totowa, NJ: Humana Press; 2008. p. 93–102.
44. Kaye M, Druce J, Tran T, et al. SARS–associated coronavirus replication in cell lines. Emerg Infect Dis. 2006;12(1):128–133. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291385/
45. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381.
46. Shen L, Yang Y, Ye F, et al. Safe and sensitive antiviral screening platform based on recombinant human coronavirus OC43 expressing the luciferase reporter gene. Antimicrob Agents Chemother. 2016;60(9):5492–5503. Available from: http://aac.asm.org/content/60/9/5492.abstract
47. Severson WE, Shindo N, Sosa M, et al. Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,000-compound library. J Biomol Screen. 2006;12(1):33–40.
48. Ge F, Xiong S, Lin F-S, et al. High-throughput assay using a GFP-expressing replicon for SARS-CoV drug discovery. Antiviral Res. 2008;80(2):107–113. Available from: http://www.sciencedirect.com/science/article/pii/S0166354208003112
49. Ghosh AK, Takayama J, Rao KV, et al. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation. J Med Chem. 2010;53(13):4968–4979. Available from: https://www.ncbi.nlm.nih.gov/pmc/PMC2918394/
50. Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885–4893. Available from: http://aac.asm.org/content/58/8/4885.abstract
51. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):p 4875. Available from: http://aac.asm.org/content/58/8/4875.abstract
52. Elshabrawy HA, Fan J, Haddad CS, et al. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. J Virol. 2014;88(8):4353–4365. Available from: http://jvi.asm.org/content/88/8/4353.abstract
53. Sims AC, Baric RS, Yount B, et al. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. 2005;79(24):15511–15524. Available from: http://jvi.asm.org/content/79/24/15511.abstract
54. Banach BS, Orenstein JM, Fox LM, et al. Human airway epithelial cell culture to identify new respiratory viruses: coronavirus NL63 as a model. J Virol Methods. 2009;156(1–2):19–26. Available from: http://www.sciencedirect.com/science/article/pii/S0166093408003807
55. Dijkman R, Jebbink MF, Koekkoek SM, et al. Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism. J Virol. 2013;87(11):6081–6090. Available from: http://jvi.asm.org/content/87/11/6081.abstract
56. Chan RWY, Hemida MG, Kayali G, et al. Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study. Lancet Respir Med. 2014;2(10):813–822. Available from: http://www.sciencedirect.com/science/article/pii/S2213260014701584
57. Niemeyer BF, Zhao P, Tuder RM, et al. Advanced microengineered lung models for translational drug discovery. SLAS Discov. 2018;23(8):777–789.
58. Cockrell AS, Leist SR, Douglas MG, et al. Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice. Mamm Genome. 2018;29(7–8):367–383. Available from: https://www.ncbi.nlm.nih.gov/pmc/PMC6132729/
59. Sutton TC, Subbarao K. Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus. Virology. 2015;479–480:247–258. Available from: http://www.sciencedirect.com/science/article/pii/S0042682215000768
60. Glass WG, Subbarao K, Murphy B, et al. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol. 2004;173(6):4030–4039. Available from: http://jimmunol.org/content/173/6/4030.abstract
61. Roberts A, Vogel L, Guarner J, et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol. 2005;79(1):503–511. Available from: http://jvi.asm.org/content/79/1/503.abstract
62. Chepurnov AA, Dadaeva AA, Malkova EM, et al. Symptoms of infection caused by SARS coronavirus in laboratory mice and guinea pigs. [Journal article]. Dokl Biol Sci. 2004;397(1–6):310–313.
63. Martina BEE, Haagmans BL, Kuiken T, et al. Virology: SARS virus infection of cats and ferrets. Nature. 2003;425(6961):915.
64. Roberts A, Deming D, Paddock CD, et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 2007;3(1):e5.
65. Day CW, Baric R, Cai SX, et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 2009;395(2):210–222. Available from: http://www.sciencedirect.com/science/article/pii/S0042682209005832
66. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396). DOI:10.1126/scitranslmed.aal3653
67. Zhao J, Wohlford-Lenane C, Zhao J, et al. Intranasal treatment with poly(I·C) protects aged mice from lethal respiratory virus infections. J Virol. 2012;86(21):11416–11424. Available from: http://jvi.asm.org/content/86/21/11416.abstract
68. Gralinski LE, Bankhead A, Jeng S, et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio. 2013;4(4). DOI:10.1128/mBio.00271-13
69. Gralinski LE, Ferris MT, Aylor DL, et al. Genome wide identification of SARS-CoV susceptibility loci using the collaborative cross. PLoS Genet. 2015;11(10):e1005504.
70. de Wit E, Prescott J, Baseler L, et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS ONE. 2013;8(7):e69127.
71. Coleman CM, Matthews KL, Goicochea L, et al. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol. 2014;95(Pt 2):408–412.
72. Raj VS, Smits SL, Provacia LB, et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J Virol. 2014;88(3):1834–1838. Available from: http://jvi.asm.org/content/88/3/1834.abstract
73. Haagmans BL, van Den Brand JMA, Provacia LB, et al. Asymptomatic Middle East Respiratory syndrome coronavirus infection in rabbits. J Virol. 2015;89(11):6131–6135. Available from: http://jvi.asm.org/content/89/11/6131.abstract
74. Houser KV, Gretebeck L, Ying T, et al. Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)–specific human monoclonal antibody protects rabbits from MERS-CoV infection. J Infect Dis. 2016;213(10):1557–1561. Available from: https://academic.oup.com/jid/article/213/10/1557/2459422
75. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Nat Acad Sci. 2014;111(13):4970–4975. Available from: http://www.pnas.org/content/111/13/4970.abstract
76. Agrawal AS, Garron T, Tao X, et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol. 2015;89(7):3659–3670. Available from: http://jvi.asm.org/content/89/7/3659.abstract
77. Li K, Wohlford-Lenane C, Perlman S, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2016;213(5):712–722. Available from: https://www.ncbi.nlm.nih.gov/pmc/PMC4747621/
78. Pascal KE, Coleman CM, Mujica AO, et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Nat Acad Sci. 2015;112:8738–8743. Available from: http://www.pnas.org/content/early/2015/06/24/1510830112.abstract
79. Li K, Wohlford-Lenane CL, Channappanavar R, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. J Proc National Acad Sci. 2017;114(15):E3119–E3128. Available from: https://www.pnas.org/content/pnas/114/15/E3119.full.pdf
80. Cockrell AS, Yount BL, Scobey T, et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. [Article]. Nat Microbiol. 2016;2:16226.
81. Kuiken T, Fouchier RAM, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362(9380):263–270.
82. Rowe T, Gao G, Hogan RJ, et al. Macaque model for severe acute respiratory syndrome. J Virol. 2004;78(20):11401–11404. Available from: http://jvi.asm.org/content/78/20/11401.abstract
83. McAuliffe J, Vogel L, Roberts A, et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology. 2004;330(1):8–15. Available from: http://www.sciencedirect.com/science/article/pii/S0042682204006087
84. Greenough TC, Carville A, Coderre J, et al. Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) Infected with the severe acute respiratory syndrome-associated coronavirus. Am J Pathol. 2005;167(2):455–463.
85. Lawler JV, Endy TP, Hensley LE, et al. Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med. 2006;3(5):e149.
86. Smits SL, van Den Brand JMA, de Lang A, et al. Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different Nonhuman primate species. J Virol. 2011;85(9):4234–4245. Available from: http://jvi.asm.org/content/85/9/4234.abstract
87. Smits SL, de Lang A, van Den Brand JMA, et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog. 2010;6(2):e1000756.
88. de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Nat Acad Sci. 2013;110(41):16598–16603. Available from: http://www.pnas.org/content/110/41/16598.abstract
89. Johnson RF, Bagci U, Keith L, et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology. 2016;490:49–58. Available from: http://www.sciencedirect.com/science/article/pii/S0042682216000076
90. Falzarano D, de Wit E, Feldmann F, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014;10(8):e1004250.
91. Johnson RF, Via LE, Kumar MR, et al. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology. 2015;485:422–430. Available from http://www.sciencedirect.com/science/article/pii/S0042682215003323
92. Chan JF-W, Yao Y, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a Nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904–1913. Available from: http://jid.oxfordjournals.org/content/212/12/1904.abstract
93. Neuman BW, Chamberlain P, Bowden F, et al. Atlas of coronavirus replicase structure. Virus Res. 2014;194:49–66. Available from: http://www.sciencedirect.com/science/article/pii/S0168170213004334
94. Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and paramyxoviruses. [Article]. Sci Rep. 2017;7:43395.
95. Dörnemann J, Burzio C, Ronsse A, et al. First newborn baby to receive experimental therapies survives ebola virus disease. J Infect Dis. 2017;215(2):171–174. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583641/
96. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2). DOI:10.1128/mBio.00221-18
97. Wu C-Y, Jan J-T, Ma S-H, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci USA. 2004;101(27):10012–10017. Available from: http://www.pnas.org/content/pnas/101/27/10012.full.pdf
98. Chu C, Cheng V, Hung I, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746980/
99. Kim UJ, Won E-J, Kee S-J, et al. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther. 2016;(21):455–459. DOI:10.3851/IMP3002
100. Bin SY, Heo JY, Song M-S, et al. Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea. Clinl Infect Dis. 2015;62(6):755–760. Available from: http://cid.oxfordjournals.org/content/early/2016/01/06/cid.civ1020.abstract
101. Arabi YM, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19(1):81.
102. Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014;95(Pt 3):571–577. Available from: http://vir.sgmjournals.org/content/95/Pt_3/571.abstract
103. Ströher U, DiCaro A, Li Y, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J Infect Dis. 2004;189(7):1164–1167. Available from: http://jid.oxfordjournals.org/content/189/7/1164.abstract
104. Falzarano D, de Wit E, Martellaro C, et al. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. [Article]. Sci Rep. 2013;3:1686. Available from: https://www.nature.com/articles/srep01686
105. Ferron F, Subissi L, Silveira De Morais AT, et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Nat Acad Sci. 2018;115(2):E162–E171. Available from: http://www.pnas.org/content/pnas/115/2/E162.full.pdf
106. Barnard DL, Day CW, Bailey K, et al. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res. 2006;71(1):53–63. Available from: http://www.sciencedirect.com/science/article/pii/S0166354206000660
107. Falzarano D, de Wit E, Rasmussen AL, et al. Interferon-α2b and ribavirin treatment improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–1317. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093902/
108. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.
109. Morra ME, Van Thanh L, Kamel MG, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol. 2018;28(3):e1977.
110. DeDiego ML, Álvarez E, Almazán F, et al. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol. 2007;81(4):1701–1713. Available from: http://jvi.asm.org/content/81/4/1701.abstract
111. Menachery VD, Mitchell HD, Cockrell AS, et al. MERS-CoV accessory ORFs play key role for infection and pathogenesis. mBio. 2017;8(4). DOI:10.1128/mBio.00665-17
112. Frieman M, Yount B, Sims A, et al. SARS coronavirus accessory ORFs encode luxury functions. In: Perlman S, Holmes K, editors. The Nidoviruses. Vol. 581. New York, NY: Springer US; 2006. p. 149–152.
113. Zhu Z, Chakraborti S, He Y, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Nat Acad Sci. 2007;104(29):12123–12128. Available from: http://www.pnas.org/content/104/29/12123.abstract
114. Agnihothram S, Gopal R, Yount BL, et al. Evaluation of serologic and antigenic relationships between Middle Eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis. 2014;209(7):995–1006. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952667/
115. Sui J, Deming M, Rockx B, et al. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J Virol. 2014;88(23):13769–13780. Available from: http://jvi.asm.org/content/88/23/13769.abstract
116. Zumla A, Dar O, Kock R, et al. Taking forward a ‘One Health’ approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential. Inter J Infect Dis. 2016;47:5–9. Available from: http://www.sciencedirect.com/science/article/pii/S1201971216310967
117. Haagmans BL, van Den Brand JMA, Raj VS, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2015. DOI:10.1126/science.aad1283
118. Bolles M, Deming D, Long K, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201–12215. Available from: http://jvi.asm.org/content/85/23/12201.abstract
119. Sheahan T, Whitmore A, Long K, et al. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol. 2011;85(1):217–230. Available from: http://jvi.asm.org/content/85/1/217.abstract
120. Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA. 2005;102(33):11876–11881. Available from: http://www.pnas.org/content/pnas/102/33/11876.full.pdf
121. Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76–84. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774534/
122. Zhou N, Pan T, Zhang J, et al. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem. 2016;291(17):9218–9232. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861487/
123. Pfefferle S, Schöpf J, Kögl M, et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011;7(10):e1002331.
124. de Wilde AH, Falzarano D, Zevenhoven-Dobbe JC, et al. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. Virus Res. 2017;228:7–13. Available from: http://www.sciencedirect.com/science/article/pii/S0168170216305524
125. Schoggins JW, Wilson SJ, Panis M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472(7344):481–485.
126. Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293–294. Available from: http://www.sciencedirect.com/science/article/pii/S0140673603139736
127. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004;10(3):290–293.